Biogen will pay Acorda to market Fampridine outside US
2009-07-04 메디칼라이터팀
Acorda Therapeutics Inc will receive an upfront payment of $110 million and up to $400 million for meeting development and sales goals for the drug from Biogen Idec Inc, so that it can market the drug, Fampridine SR outside the US. Although the drug faces regulatory hurdles and side effect concerns, most see it as a safe treatment which dramatically improves quality of life for MS sufferers who have difficulty walking.